Atopic Dermatitis (AD) is a non-infectious, chronic, recurrent, inflammatory skin disease. The cause of AD is complex and multidimensional, and the disease manifests differently in each individual. Biologics comprise monoclonal antibodies such as Dupilumab and small-molecule inhibitors such as Crisaborole. JAK inhibitors are the most promising biologics, giving us a new frontier against AD. Several nations have approved Baricitinib, Upadacitinib, and Abrocitinib, among others. Additional clinical trials are necessary to thoroughly assess the safety and durability of a treatment over the long term. This thesis talks about Atopic Dermatitis, its conventional therapy, and discusses at length novel therapies, i.e., biologics.